SARS-CoV-2 vaccines in development

A novel coronavirus from patients with pneumonia in China, 2019

Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001017 · Cited by 28,244

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897

Origin and evolution of pathogenic coronaviruses

Cui, J., Li, F., & Shi, Z. (2018) · Nature Reviews Microbiology · doi:10.1038/s41579-018-0118-9 · Cited by 5,729

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals

Grifoni, A., Weiskopf, D., Ramirez, S. I., Mateus, J., Dan, J. M., Moderbacher, C. R., Rawlings, S. A., Sutherland, A., Premkumar, L., Jadi, R. S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.015 · Cited by 3,595

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,237

Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses

Letko, M., Marzi, A., & Munster, V. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0688-y · Cited by 3,109

RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study

Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Folegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419

Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS–coronavirus 2

Shi, J., Wen, Z., Zhong, G., Yang, H., Wang, C., Huang, B., Liu, R., He, X., Shuai, L., Sun, Z., et al. (2020) · Science · doi:10.1126/science.abb7015 · Cited by 1,952

A serological assay to detect SARS-CoV-2 seroconversion in humans

(2020) · doi:10.1101/2020.03.17.20037713 · Cited by 1,769

A serological assay to detect SARS-CoV-2 seroconversion in humans

Amanat, F., Stadlbauer, D., Strohmeier, S., Nguyen, T. H. O., Chromikova, V., McMahon, M., Jiang, K., Arunkumar, G. A., Jurczyszak, D., Polanco, J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0913-5 · Cited by 1,769

SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness

Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., et al. (2020) · Nature · doi:10.1038/s41586-020-2622-0 · Cited by 1,615

Severe Acute Respiratory Syndrome Coronavirus 2−Specific Antibody Responses in Coronavirus Disease Patients

Okba, N. M. A., Müller, M. A., Li, W., Wang, C., GeurtsvanKessel, C. H., Corman, V. M., Lamers, M. M., Sikkema, R. S., de Bruin, E., Chandler, F. D., et al. (2020) · Emerging Infectious Diseases · doi:10.3201/eid2607.200841 · Cited by 1,614

Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report

Mulligan, M. J., Lyke, K. E., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Raabe, V., Bailey, R., Swanson, K. A., et al. (2020) · doi:10.1101/2020.06.30.20142570 · Cited by 1,569

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

Zhang, Y., Zeng, G., Pan, H., Li, C., Hu, Y., Chu, K., Han, W., Chen, Z., Tang, R., Yin, W., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30843-4 · Cited by 1,504

Development of an inactivated vaccine candidate for SARS-CoV-2

Gao, Q., Bao, L., Mao, H., Wang, L., Xu, K., Yang, M., Li, Y., Zhu, L., Wang, N., Lv, Z., et al. (2020) · Science · doi:10.1126/science.abc1932 · Cited by 1,434

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial

Zhu, F.-C., Li, Y.-H., Guan, X.-H., Hou, L.-H., Wang, W.-J., Li, J.-X., Wu, S.-P., Wang, B.-S., Wang, Z., Wang, L., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31208-3 · Cited by 1,382

Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike

Liu, L., Wang, P., Nair, M. S., Yu, J., Rapp, M., Wang, Q., Luo, Y., Chan, J. F.-W., Sahi, V., Figueroa, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2571-7 · Cited by 1,349

Pathogenesis and transmission of SARS-CoV-2 in golden hamsters

Sia, S. F., Yan, L.-M., Chin, A. W. H., Fung, K., Choy, K.-T., Wong, A. Y. L., Kaewpreedee, P., Perera, R. A. P. M., Poon, L. L. M., Nicholls, J. M., et al. (2020) · Nature · doi:10.1038/s41586-020-2342-5 · Cited by 1,342

Structure-based design of prefusion-stabilized SARS-CoV-2 spikes

Hsieh, C.-L., Goldsmith, J. A., Schaub, J. M., DiVenere, A. M., Kuo, H.-C., Javanmardi, K., Le, K. C., Wrapp, D., Lee, A. G., Liu, Y., et al. (2020) · Science · doi:10.1126/science.abd0826 · Cited by 1,303

Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial

Zhu, F.-C., Guan, X.-H., Li, Y.-H., Huang, J.-Y., Jiang, T., Hou, L.-H., Li, J.-X., Yang, B.-F., Wang, L., Wang, W.-J., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31605-6 · Cited by 1,225

Robust neutralizing antibodies to SARS-CoV-2 infection persist for months

Wajnberg, A., Amanat, F., Firpo, A., Altman, D. R., Bailey, M. J., Mansour, M., McMahon, M., Meade, P., Mendu, D. R., Muellers, K., et al. (2020) · Science · doi:10.1126/science.abd7728 · Cited by 1,195

Robust neutralizing antibodies to SARS-CoV-2 infection persist for months

(2020) · Science · doi:10.1101/2020.07.14.20151126 · Cited by 1,192

Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

Keech, C., Albert, G., Cho, I., Robertson, A., Reed, P., Neal, S., Plested, J. S., Zhu, M., Cloney-Clark, S., Zhou, H., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2026920 · Cited by 1,156

The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice

Bao, L., Deng, W., Huang, B., Gao, H., Liu, J., Ren, L., Wei, Q., Yu, P., Xu, Y., Qi, F., et al. (2020) · Nature · doi:10.1038/s41586-020-2312-y · Cited by 1,126

Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen

Pallesen, J., Wang, N., Corbett, K. S., Wrapp, D., Kirchdoerfer, R. N., Turner, H. L., Cottrell, C. A., Becker, M. M., Wang, L., Shi, W., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1707304114 · Cited by 1,073

Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates

Corbett, K. S., Flynn, B., Foulds, K. E., Francica, J. R., Boyoglu-Barnum, S., Werner, A. P., Flach, B., O’Connell, S., Bock, K. W., Minai, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024671 · Cited by 1,066

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia

Logunov, D. Y., Dolzhikova, I. V., Zubkova, O. V., Tukhvatulin, A. I., Shcheblyakov, D. V., Dzharullaeva, A. S., Grousova, D. M., Erokhova, A. S., Kovyrshina, A. V., Botikov, A. G., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31866-3 · Cited by 1,055

Cryo-EM Structure of the 2019-nCoV Spike in the Prefusion ConformationPreprint

Wrapp, D., Wang, N., Corbett, K. S., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.02.11.944462 · Cited by 1,010

DNA vaccine protection against SARS-CoV-2 in rhesus macaques

Yu, J., Tostanoski, L. H., Peter, L., Mercado, N. B., McMahan, K., Mahrokhian, S. H., Nkolola, J. P., Liu, J., Li, Z., Chandrashekar, A., et al. (2020) · Science · doi:10.1126/science.abc6284 · Cited by 997

Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development

Imai, M., Iwatsuki‐Horimoto, K., Hatta, M., Loeber, S. J., Halfmann, P., Nakajima, N., Watanabe, T., Ujie, M., Takahashi, K., Ito, M., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2009799117 · Cited by 994

ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques

van Doremalen, N., Lambe, T., Spencer, A., Belij-Rammerstorfer, S., Purushotham, J. N., Port, J. R., Avanzato, V. A., Bushmaker, T., Flaxman, A., Ulaszewska, M., et al. (2020) · Nature · doi:10.1038/s41586-020-2608-y · Cited by 914

Infection and Rapid Transmission of SARS-CoV-2 in Ferrets

Kim, Y., Kim, S.-G., Kim, S.-M., Kim, E.-H., Park, S.-J., Yu, K.-M., Chang, J.-H., Kim, E. J., Lee, S., Casel, M. A. B., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.03.023 · Cited by 883

Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients

Isho, B., Abe, K. T., Zuo, M., Jamal, A. J., Rathod, B., Wang, J. H., Li, Z., Chao, G., Rojas, O. L., Bang, Y. M., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.abe5511 · Cited by 822

SARS-CoV-2 infection protects against rechallenge in rhesus macaques

Chandrashekar, A., Liu, J., Martinot, A. J., McMahan, K., Mercado, N. B., Peter, L., Tostanoski, L. H., Yu, J., Maliga, Z., Nekorchuk, M., et al. (2020) · Science · doi:10.1126/science.abc4776 · Cited by 816

Single-Shot Ad26 Vaccine Protects Against SARS-CoV-2 in Rhesus Macaques

Mercado, N. B., Zahn, R., Wegmann, F., Loos, C., Chandrashekar, A., Yu, J., Liu, J., Peter, L., McMahan, K., Tostanoski, L. H., et al. (2020) · Nature · doi:10.1038/s41586-020-2607-z · Cited by 789

Structural insights into coronavirus entry

(2019) · Advances in Virus Research · doi:10.1016/bs.aivir.2019.08.002 · Cited by 769

Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes

Xia, S., Duan, K., Zhang, Y., Zhao, D., Zhang, H., Xie, Z., Li, X., Peng, C., Zhang, Y., Zhang, W., et al. (2020) · JAMA · doi:10.1001/jama.2020.15543 · Cited by 768

Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy

Gu, H., Chen, Q., Yang, G., He, L., Fan, H., Deng, Y.-Q., Wang, Y., Teng, Y., Zhao, Z., Cui, Y., et al. (2020) · Science · doi:10.1126/science.abc4730 · Cited by 762

Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2

Wang, H., Zhang, Y., Huang, B., Deng, W., Quan, Y., Wang, W., Xu, W., Zhao, Y., Li, N., Zhang, J., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.008 · Cited by 748

Respiratory disease in rhesus macaques inoculated with SARS-CoV-2

Munster, V. J., Feldmann, F., Williamson, B. N., van Doremalen, N., Pérez-Pérez, L., Schulz, J., Meade-White, K., Okumura, A., Callison, J., Brumbaugh, B., et al. (2020) · Nature · doi:10.1038/s41586-020-2324-7 · Cited by 720

SARS coronavirus entry into host cells through a novel clathrin- and caveolae-independent endocytic pathway

Wang, H., Yang, P., Liu, K., Guo, F., Zhang, Y., Zhang, G., & Jiang, C. (2008) · Cell Research · doi:10.1038/cr.2008.15 · Cited by 700

Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2

Williamson, B. N., Feldmann, F., Schwarz, B. H., Meade-White, K. D., Porter, D., Schulz, J. E., van Doremalen, N., Leighton, I. A., Yinda, C. K., Pérez-Pérez, L., et al. (2020) · Nature · doi:10.1038/s41586-020-2423-5 · Cited by 696

A decade after SARS: strategies for controlling emerging coronaviruses

Graham, R. L., Donaldson, E., & Baric, R. S. (2013) · Nature Reviews Microbiology · doi:10.1038/nrmicro3143 · Cited by 689

A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures

Dinnon, K. H., Leist, S. R., Schäfer, A., Edwards, C. E., Martinez, D. R., Montgomery, S. A., West, A., Yount, B. L., Hou, Y. J., Adams, L. E., et al. (2020) · Nature · doi:10.1038/s41586-020-2708-8 · Cited by 675

Complete Genomic Sequence of Human Coronavirus OC43: Molecular Clock Analysis Suggests a Relatively Recent Zoonotic Coronavirus Transmission Event

Vijgen, L., Keyaerts, E., Moës, E., Thoelen, I., Wollants, E., Lemey, P., Vandamme, A., & Ranst, M. A. V. (2005) · Journal of Virology · doi:10.1128/jvi.79.3.1595-1604.2005 · Cited by 590

Structure-based Design of Prefusion-stabilized SARS-CoV-2 SpikesPreprint

Hsieh, C., Goldsmith, J., Schaub, J. M., et al. (2020) · bioRxiv · doi:10.1101/2020.05.30.125484 · Cited by 588

Immunization with SARS Coronavirus Vaccines Leads to Pulmonary Immunopathology on Challenge with the SARS Virus

Tseng, C.-T. K., Sbrana, E., Iwata‐Yoshikawa, N., Newman, P. C., Garron, T. M., Atmar, R. L., Peters, C. J., & Couch, R. B. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035421 · Cited by 562

Pathogenesis of SARS-CoV-2 in Transgenic Mice Expressing Human Angiotensin-Converting Enzyme 2

Jiang, R.-D., Liu, M.-Q., Chen, Y., Shan, C., Zhou, Y.-W., Shen, X.-R., Li, Q., Zhang, L., Zhu, Y., Si, H.-R., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.027 · Cited by 548

Neutralizing antibodies correlate with protection from SARS-CoV-2 in humans during a fishery vessel outbreak with a high attack rate

Addetia, A., Crawford, K. H. D., Dingens, A., Zhu, H., Roychoudhury, P., Huang, M.-L., Jerome, K. R., Bloom, J. D., & Greninger, A. L. (2020) · Journal of Clinical Microbiology · doi:10.1128/jcm.02107-20 · Cited by 525

Self-amplifying RNA vaccines give equivalent protection against influenza to mRNA vaccines but at much lower doses

Vogel, A. B., Lambert, L., Kinnear, E., Busse, D., Erbar, S., Reuter, K. C., Wicke, L., Perkovic, M., Beissert, T., Haas, H., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.11.017 · Cited by 501

A SARS-CoV-2 Infection Model in Mice Demonstrates Protection by Neutralizing Antibodies

Hassan, A. O., Case, J. B., Winkler, E. S., Thackray, L. B., Kafai, N. M., Bailey, A. L., McCune, B. T., Fox, J. M., Chen, R. E., Alsoussi, W. B., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.011 · Cited by 482

A Double-Inactivated Severe Acute Respiratory Syndrome Coronavirus Vaccine Provides Incomplete Protection in Mice and Induces Increased Eosinophilic Proinflammatory Pulmonary Response upon Challenge

Bolles, M., Deming, D., Long, K., Agnihothram, S., Whitmore, A., Ferris, M., Funkhouser, W., Gralinski, L., Totura, A., Heise, M., et al. (2011) · Journal of Virology · doi:10.1128/jvi.06048-11 · Cited by 477

SARS-CoV-2 is transmitted via contact and via the air between ferrets

Richard, M., Kok, A., de Meulder, D., Bestebroer, T. M., Lamers, M. M., Okba, N. M. A., van Vlissingen, M. F., Rockx, B., Haagmans, B. L., Koopmans, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17367-2 · Cited by 450

Generation of a Broadly Useful Model for COVID-19 Pathogenesis, Vaccination, and Treatment

Sun, J., Zhuang, Z., Zheng, J. H., Li, K., Wong, R. L.-Y., Liu, D., Huang, J., He, J., Zhu, A., Zhao, J., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.010 · Cited by 440

Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques

Deng, W., Bao, L., Liu, J., Xiao, C., Liu, J., Xue, J., Lv, Q., Qi, F., Gao, H., Yu, P., et al. (2020) · Science · doi:10.1126/science.abc5343 · Cited by 440

Lack of Reinfection in Rhesus Macaques Infected with SARS-CoV-2

Bao, L., Deng, W., Gao, H., Xiao, C., Liu, J., Xue, J., Lv, Q., Liu, J., Yu, P., Xu, Y., et al. (2020) · doi:10.1101/2020.03.13.990226 · Cited by 419

Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins

Wang, S., Tseng, S., Yen, C., Yang, J.-Y., Tsao, C.-H., Shen, C.-W., Chen, K.-H., Liu, F., Liu, W.-T., Chen, Y. A., et al. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.07.090 · Cited by 417

Receptor-mediated Immunoglobulin G Transport Across Mucosal Barriers in Adult Life

Spiekermann, G. M., Finn, P. W., Ward, E. S., Dumont, J., Dickinson, B. L., Blumberg, R. S., & Lencer, W. I. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020400 · Cited by 413

A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice

Laczko, D. I., Hogan, M. J., Toulmin, S. A., Hicks, P. D., Lederer, K., Gaudette, B. T., Castaño, D., Amanat, F., Muramatsu, H., Oguin, T. H., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.07.019 · Cited by 355

Influenza A and B viruses expressing altered NS1 proteins: A vaccine approach

Talon, J., Salvatore, M., O’Neill, R. E., Nakaya, Y., Zheng, H., Muster, T., García‐Sastre, A., & Palese, P. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.070525997 · Cited by 320

Immunodominant SARS Coronavirus Epitopes in Humans Elicited both Enhancing and Neutralizing Effects on Infection in Non-human Primates

Wang, Q., Zhang, L., Kuwahara, K., Li, L., Liu, Z., Li, T., Zhu, H., Liu, J., Xu, Y., Xie, J., et al. (2016) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.6b00006 · Cited by 299

Vaccine Efficacy in Senescent Mice Challenged with Recombinant SARS-CoV Bearing Epidemic and Zoonotic Spike Variants

Deming, D., Sheahan, T. P., Heise, M. T., Yount, B. L., Davis, N., Sims, A. M., Suthar, M. S., Harkema, J. R., Whitmore, A. C., Pickles, R. J., et al. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030525 · Cited by 273

A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial

Martin, J. E., Louder, M. K., Holman, L. A., Gordon, I. J., Enama, M. E., Larkin, B. D., Andrews, C. A., Vogel, L., Koup, R. A., Roederer, M., et al. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.09.026 · Cited by 267

Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus

Agrawal, A. S., Tao, X., Algaissi, A. A., Garron, T. M., Narayanan, K., Peng, B., Couch, R. B., & Tseng, C.-T. K. (2016) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2016.1177688 · Cited by 267

COVID-19 Serology at Population Scale: SARS-CoV-2-Specific Antibody Responses in Saliva

Randad, P. R., Pisanic, N., Kruczynski, K. L., Manabe, Y. C., Thomas, D. L., Pekosz, A. S., Klein, S. L., Betenbaugh, M. J., Clarke, W. A., Laeyendecker, O. B., et al. (2020) · Journal of Clinical Microbiology · doi:10.1128/jcm.02204-20 · Cited by 249

Infection with novel coronavirus (SARS-CoV-2) causes pneumonia in Rhesus macaques

Shan, C., Yao, Y., Yang, X., Zhou, Y., Gao, G., Peng, Y., Yang, L., Hu, X., Xiong, J., Jiang, R.-D., et al. (2020) · Cell Research · doi:10.1038/s41422-020-0364-z · Cited by 241

NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge

Guebre-Xabier, M., Patel, N., Tian, J.-H., Zhou, B., Maciejewski, S., Lam, K., Portnoff, A. D., Massare, M. J., Frieman, M. B., Piedra, P. A., et al. (2020) · Vaccine · doi:10.1016/j.vaccine.2020.10.064 · Cited by 231

Recent Advances in the Vaccine Development Against Middle East Respiratory Syndrome-Coronavirus

Yong, C. Y., Ong, H. K., Yeap, S. K., Ho, K. L., & Tan, W. S. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.01781 · Cited by 224

Granzyme B: Correlates with protection and enhanced CTL response to influenza vaccination in older adults

McElhaney, J. E., Ewen, C., Zhou, X., Kane, K. P., Xie, D., Hager, W. D., Barry, M. B., Kleppinger, A., Wang, Y., & Bleackley, R. C. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.01.136 · Cited by 219

Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate FcγRII-dependent entry into B cells in vitro

Kam, Y., Kien, F., Roberts, A., Cheung, Y. C., Lamirande, E. W., Vogel, L., Chu, S. L., Tse, J., Guarner, J., Zaki, S. R., et al. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.08.011 · Cited by 210

Comparison of transgenic and adenovirus hACE2 mouse models for SARS-CoV-2 infection

Rathnasinghe, R., Strohmeier, S., Amanat, F., Gillespie, V., Krammer, F., García‐Sastre, A., Coughlan, L., Schotsaert, M., & Uccellini, M. B. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1838955 · Cited by 198

Replication-Competent Vesicular Stomatitis Virus Vaccine Vector Protects against SARS-CoV-2-Mediated Pathogenesis in Mice

Case, J. B., Rothlauf, P. W., Chen, R. E., Kafai, N. M., Fox, J. M., Smith, B. K., Shrihari, S., McCune, B. T., Harvey, I. B., Keeler, S. P., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.07.018 · Cited by 185

A Potently Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection

Alsoussi, W. B., Turner, J. S., Case, J. B., Zhao, H., Schmitz, A. J., Zhou, J. Q., Chen, R. E., Lei, T., Rizk, A. A., McIntire, K. M., et al. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.2000583 · Cited by 181

Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets

CZUB, M., WEINGARTL, H., CZUB, S., HE, R., & CAO, J. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.01.033 · Cited by 180

Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2Preprint

Williamson, B. N., Feldmann, F., Schwarz, B. H., Meade-White, K. D., Porter, D., Schulz, J. E., van Doremalen, N., Leighton, I. A., Yinda, C. K., Pérez-Pérez, L., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.04.15.043166 · Cited by 180

Safety and Immunogenicity from a Phase I Trial of Inactivated Severe Acute Respiratory Syndrome Coronavirus Vaccine

Lin, J., Zhang, J., Su, N., Xu, J., Wang, N., Chen, J.-T., Chen, X., Liu, Y.-X., Gao, H., Jia, Y.-P., et al. (2007) · Antiviral Therapy · doi:10.1177/135965350701200702 · Cited by 168

Induction of mucosal immunity through systemic immunization: Phantom or reality?

Su, F., Patel, G. B., Hu, S., & Chen, W. (2016) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1114195 · Cited by 161

A COVID-19 mRNA vaccine encoding SARS-CoV-2 virus-like particles induces a strong antiviral-like immune response in mice

Lu, J., Lu, G., Tan, S., Jia Hui, X. I. A., Xiong, H., Yu, X., Qi, Q., Yu, X., Li, L., Yu, H., et al. (2020) · Cell Research · doi:10.1038/s41422-020-00392-7 · Cited by 147

Dynamics and significance of the antibody response to SARS-CoV-2 infectionPreprint

Iyer, A., Jones, F. K., Nodoushani, A., Kelly, M., Becker, M. V., Slater, D., Mills, R., Teng, E., Kamruzzaman, M., Garcia-Beltran, W., et al. (2020) · medRxiv · doi:10.1101/2020.07.18.20155374 · Cited by 143

Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19

Graham, S. P., McLean, R. K., Spencer, A. J., Belij‐Rammerstorfer, S., Wright, D., Ulaszewska, M., Edwards, J. C., Hayes, J. W. P., Martini, V., Thakur, N., et al. (2020) · npj Vaccines · doi:10.1038/s41541-020-00221-3 · Cited by 138

High-dose trivalent influenza vaccine compared to standard dose vaccine in elderly adults: Safety, immunogenicity and relative efficacy during the 2009–2010 season

DiazGranados, C. A., Dunning, A. J., Jordanov, E., Landolfi, V. A., Denis, M., & Talbot, H. K. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.12.013 · Cited by 123

Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as a live virus vaccine candidate

Sun, W., Leist, S. R., McCroskery, S., Liu, Y., Slamanig, S., Oliva, J., Amanat, F., Schäfer, A., Dinnon, K. H., García‐Sastre, A., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.103132 · Cited by 118

Immunoglobulin G and Its Function in the Human Respiratory Tract

Reynolds, H. Y. (1988) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(12)64949-0 · Cited by 112

Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with aluminum hydroxide induces protective immunity and reduces immune enhancement

Chen, W., Tao, X., Agrawal, A. S., Algaissi, A. A., Peng, B., Pollet, J. B. K., Strych, U., Bottazzi, M. E., Hotez, P. J., Lustigman, S., et al. (2020) · Vaccine · doi:10.1016/j.vaccine.2020.09.061 · Cited by 104

Correlates of Protection against Influenza in the Elderly: Results from an Influenza Vaccine Efficacy Trial

Dunning, A. J., DiazGranados, C. A., Voloshen, T., Hu, B. T., Landolfi, V. A., & Talbot, H. K. (2016) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00604-15 · Cited by 101

Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 years: Report of the Randomized, Double-blind, and Placebo-controlled Phase 2 Clinical TrialPreprint

Zhang, Y., Zeng, G., Pan, H., et al. (2020) · medRxiv · doi:10.1101/2020.07.31.20161216 · Cited by 96

A Newcastle Disease Virus (NDV) Expressing a Membrane-Anchored Spike as a Cost-Effective Inactivated SARS-CoV-2 Vaccine

Sun, W., McCroskery, S., Liu, W., Leist, S. R., Liu, Y., Albrecht, R. A., Slamanig, S., Oliva, J., Amanat, F., Schäfer, A., et al. (2020) · Vaccines · doi:10.3390/vaccines8040771 · Cited by 95

Expression of Homing Receptors on IgA1 and IgA2 Plasmablasts in Blood Reflects Differential Distribution of IgA1 and IgA2 in Various Body Fluids

Pakkanen, S. H., Kantele, J. M., Moldoveanu, Z., Hedges, S. R., Häkkinen, M., Mestecky, J. F., & Kantele, A. (2010) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00475-09 · Cited by 91

Enhanced inflammation in New Zealand white rabbits when MERS-CoV reinfection occurs in the absence of neutralizing antibody

Houser, K. V., Broadbent, A., Gretebeck, L., Vogel, L., Lamirande, E. W., Sutton, T. C., Bock, K. W., Minai, M., Orandle, M. S., Moore, I. N., et al. (2017) · PLoS Pathogens · doi:10.1371/journal.ppat.1006565 · Cited by 88

Direct visualization of translational GTPase factor pool formed around the archaeal ribosomal P-stalk by high-speed AFM

Imai, H., Uchiumi, T., & Kodera, N. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2018975117 · Cited by 88

Introduction of Two Prolines and Removal of the Polybasic Cleavage Site Lead to Higher Efficacy of a Recombinant Spike-Based SARS-CoV-2 Vaccine in the Mouse Model

Amanat, F., Strohmeier, S., Rathnasinghe, R., Schotsaert, M., Coughlan, L., García‐Sastre, A., & Krammer, F. (2021) · mBio · doi:10.1128/mbio.02648-20 · Cited by 86

COVID-19 serology at population scale: SARS-CoV-2-specific antibody responses in salivaPreprint

Randad, P. R., Pisanic, N., Kruczynski, K. L., et al. (2020) · medRxiv · doi:10.1101/2020.05.24.20112300 · Cited by 80

Evaluation of the attenuation, immunogenicity, and efficacy of a live virus vaccine generated by codon-pair bias de-optimization of the 2009 pandemic H1N1 influenza virus, in ferrets

Broadbent, A. J., Santos, C. P., Anafu, A., Wimmer, E., Mueller, S., & Subbarao, K. (2016) · Vaccine · doi:10.1016/j.vaccine.2015.11.054 · Cited by 79

SARS-CoV-2 is transmitted via contact and via the air between ferretsPreprint

Richard, M., Kok, A., de Meulder, D., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.04.16.044503 · Cited by 66

Delayed severe cytokine storm and immune cell infiltration in SARS-CoV-2-infected aged Chinese rhesus macaques

Song, T., 昆明650223，中国, 中.-C., Zheng, H., Han, J.-B., Jin, L., Yang, X. S., Liu, F., Luo, R., Tian, R., Cai, H., et al. (2020) · 动物学研究 · doi:10.24272/j.issn.2095-8137.2020.202 · Cited by 63

Comparison of Transgenic and Adenovirus hACE2 Mouse Models for SARS-CoV-2 InfectionPreprint

Rathnasinghe, R., Strohmeier, S., Amanat, F., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.07.06.190066 · Cited by 56

Mucosal versus systemic antibody responses to SARS-CoV-2 antigens in COVID-19 patientsPreprint

Isho, B., Abe, K. T., Zuo, M., et al. (2020) · medRxiv · doi:10.1101/2020.08.01.20166553 · Cited by 54

Barbiturate and hypnosedative withdrawal by a multiple oral phenobarbital loading dose technique

Robinson, G., Sellers, E. M., & Janecek, E. (1981) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1981.129 · Cited by 43

First-in-Human Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle VaccinePreprint

Keech, C. A., Glenn, G. M., Albert, G. R., et al. (2020) · medRxiv · doi:10.1101/2020.08.05.20168435 · Cited by 43

Receptor-binding domain of SARS-Cov spike protein: Soluble expression inE.coli, purification and functional characterization

Chen, J. (2005) · World Journal of Gastroenterology · doi:10.3748/wjg.v11.i39.6159 · Cited by 40

A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccinePreprint

Sun, W., McCroskery, S., Liu, W., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.07.30.229120 · Cited by 40

Yeast-Expressed SARS-CoV Recombinant Receptor-Binding Domain (RBD219-N1) Formulated with Aluminum Hydroxide Induces Protective Immunity and Reduces Immune EnhancementPreprint

Chen, W., Tao, X., Agrawal, A. S., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.05.15.098079 · Cited by 38

NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challengePreprint

Guebre‐Xabier, M., Patel, N., Tian, J.-H., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.08.18.256578 · Cited by 34

Improving pandemic H5N1 influenza vaccines by combining different vaccine platforms

Luke, C. J., & Subbarao, K. (2014) · Expert Review of Vaccines · doi:10.1586/14760584.2014.922416 · Cited by 29

Evaluation of the susceptibility of mice & hamsters to SARS-CoV-2 infection

Mohandas, S., Jain, R., Yadav, P. D., Shete-Aich, A., Sarkale, P., Kadam, M., Kumar, A., Deshpande, G. R., Baradkar, S., Patil, S., et al. (2020) · The Indian Journal of Medical Research · doi:10.4103/ijmr.ijmr_2235_20 · Cited by 26

[Effects of noise and vibration during embryogenesis on fetal development and postnatal growth of the mouse].

Briese, V., Fanghänel, J., Briese, A., & Gasow, H. (1982) · PubMed · Cited by 22

Introduction of two prolines and removal of the polybasic cleavage site leads to optimal efficacy of a recombinant spike based SARS-CoV-2 vaccine in the mouse modelPreprint

Amanat, F., Strohmeier, S., Rathnasinghe, R., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.09.16.300970 · Cited by 22

A Scalable Topical Vectored Vaccine Candidate against SARS-CoV-2

Rohaim, M. A., & Munir, M. (2020) · Vaccines · doi:10.3390/vaccines8030472 · Cited by 20

Evaluation of Risks and Benefits Associated with Vaccination against Coronavirus Infections in Cats

Scott, F. W. (1999) · Advances in veterinary medicine · doi:10.1016/s0065-3519(99)80026-3 · Cited by 14

Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19Preprint

Graham, S. P., McLean, R. K., Spencer, A. J., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.06.20.159715 · Cited by 13

Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as vaccine candidatePreprint

Sun, W., Leist, S. R., McCroskery, S., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.07.26.221861 · Cited by 11

Receptor-binding domain of SARS-Cov spike protein： Soluble expression in E.coli,purification and functional characterization

Jing, J., Chen, Lin, Miao, M., Jiaming, Li, ‡., Yan-ying, Qingyu, Zhu, Z., Changlin, et al. (2005) · Acta Scientiarum Naturalium Universitatis Sunyatseni · Cited by 3

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection.

Dan, J. M., Mateus, J., Kato, Y., Hastie, K. M., Yu, E. D., Faliti, C. E., Grifoni, A., Ramirez, S. I., Haupt, S., Frazier, A., et al. (2021) · Science · doi:10.1126/science.abf4063 · Cited by 2,656

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

Sadoff, J., Gray, G., Vandebosch, A., Cárdenas, V., Shukarev, G., Grinsztejn, B., Goepfert, P. A., Truyers, C., Fennema, H., Spiessens, B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2101544 · Cited by 2,397

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7

Wang, P., Nair, M. S., Liu, L., Iketani, S., Luo, Y., Guo, Y., Wang, M., Yu, J., Zhang, B., Kwong, P. D., et al. (2021) · Nature · doi:10.1038/s41586-021-03398-2 · Cited by 2,312

Adaptive immunity to SARS-CoV-2 and COVID-19

Sette, A., & Crotty, S. (2021) · Cell · doi:10.1016/j.cell.2021.01.007 · Cited by 1,860

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

Zhang, Y., Zeng, G., Pan, H., Li, C., Hu, Y., Chu, K., Han, W., Chen, Z., Tang, R., Yin, W., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30843-4 · Cited by 1,504

Viral Vaccines and Current Status of Vaccine Developing Studies Against Novel SARS Coronavirus-2

Keşli, R. (2020) · BOĞAZİÇİ TIP DERGİSİ · doi:10.14744/bmj.2020.84755

SARS-CoV-2 Vaccine Development: An Overview and Perspectives

Liu, Y., Wang, K., Massoud, T. F., & Paulmurugan, R. (2020) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00109 · Cited by 40

Phase III Vaccines for SARS-CoV-2: A Review of Development and Available Data

Ehsan, H. S. A., Sana, M. K., Sarwar, A., Hanif, N., & Khan, S. R. (2020) · Internal Medicine Review · doi:10.18103/imr.v6i5.905

The 2020 Pandemic: Current SARS-CoV-2 Vaccine Development

Alturki, S. O., Alturki, S. O., Connors, J. R., Cusimano, G. M., Kutzler, M. A., Izmirly, A. M., & Haddad, E. K. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01880 · Cited by 80

Latest in COVID-19 Vaccine 'Candidates' Race

Atoum, M. F. M., Zreig, D. A., & Zreig, L. M. A. (2022) · Infectious Disorders - Drug Targets · doi:10.2174/1871526522666220818124416